LARRY K BROADWELL MD NPI 1326194036

NPI Details

Larry K Broadwell, MD is a rheumatology internal medicine in Shreveport, LA with 50 years of experience. The provider is an internist who treats diseases of joints, muscle, bones and tendons. This specialist diagnoses and treats arthritis, back pain, muscle strains, common athletic injuries and collagen diseases. Larry K Broadwell, MD NPI is 1326194036. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE IN SHREVEPORT
Graduation Year:1976

The provider's business location address is:

820 JORDAN ST
SUITE 201
SHREVEPORT, LA
ZIP 71101-518
Phone: (318) 221-0399
Fax: (318) 221-1940

The NPI 1326194036 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, golimumab, 1 mg, for intravenous use (HCPCS:J1602)
• Injection, tocilizumab, 1 mg (HCPCS:J3262)
• Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS:J0717)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, romosozumab-aqqg, 1 mg (HCPCS:J3111)
• Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS:J0129)
• Injection, rituximab, 10 mg (HCPCS:J9312)
• Injection, infliximab, excludes biosimilar, 10 mg (HCPCS:J1745)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, triamcinolone acetonide, not otherwise specified, 10 mg (HCPCS:J3301)
• X-ray of wrist, 2 views (HCPCS:73100)
• X-ray of hand, minimum of 3 views (HCPCS:73130)
• X-ray of foot, minimum of 3 views (HCPCS:73630)
• Dxa bone density measurement of hip, pelvis, spine (HCPCS:77080)
• X-ray of middle spine, 3 views (HCPCS:72072)
• X-ray of lower and sacral spine, 2-3 views (HCPCS:72100)
• X-ray of upper spine, 4-5 views (HCPCS:72050)
• X-ray of both hips, 2 views (HCPCS:73521)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• X-ray of knee, 4 or more views (HCPCS:73564)
• X-ray of shoulder, minimum of 2 views (HCPCS:73030)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Aspiration and/or injection of fluid large joint using ultrasound guidance (HCPCS:20611)
• Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg (HCPCS:J0702)
• Aspiration and/or injection of fluid from medium joint using ultrasound guidance (HCPCS:20606)
• X-ray of lower and sacral spine, minimum of 4 views (HCPCS:72110)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Aspiration and/or injection of fluid from small joint using ultrasound guidance (HCPCS:20604)
• X-ray of both hips, 3-4 views (HCPCS:73522)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0220)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection into tendon or ligament (HCPCS:20550)
• Ultrasonic guidance for needle placement (HCPCS:76942)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)

The enumeration date for this NPI number is 1/26/2007 and was last updated on 11/16/2007.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.